Deadly blood clots, risky treatments: The high-stakes battle against deep vein thrombosis in sports and beyond

Published Date: 14 May 2025

Seven-time NBA All-Star Damian Lillard, 34, recently joined a growing list of NBA athletes to be sidelined by a diagnosis of deep-vein thrombosis, or DVT.

Read Full News

Latest News

Lentigo Maligna Rarely Progresses Despite Rising Incidence

Despite rising cases in recent years, lentigo maligna shows minimal progression to melanoma, and patients with this condition are more likely to die due to other factors, a retrospective study finds.

Baxdrostat Approval May Open Doors for HTN Therapy

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.

Eating for One: The Future of Personalized Nutrition

Nutrition science is closing in on truly personalized dietary advice. The bigger challenge? Making sure it does not only land on wealthy plates.

When the Defibrillator Stays in Its Box

After teenage footballer Adam Ankers died in cardiac arrest while a defibrillator sat unused on the pitch, 13 organisations now have until June to respond to a coroner's report.

Is Hypertension Undertreated in Pediatrics?

Long-term implications may be underestimated, and new data show relatively low medication use.

Prior Auth Rules Vary Widely Across Insurers, Study Finds

A new study finds that prior authorization requirements vary widely across major insurers and suggests large language models could help streamline how authorization rules are interpreted and processed.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Despite rising cases in recent years, lentigo maligna shows minimal progression to melanoma, and patients with this condition are more likely to die due to other factors, a retrospective study finds.

The FDA’s recent approval of baxdrostat may usher in new possibilities for treatment for uncontrolled hypertension.

Nutrition science is closing in on truly personalized dietary advice. The bigger challenge? Making sure it does not only land on wealthy plates.

After teenage footballer Adam Ankers died in cardiac arrest while a defibrillator sat unused on the pitch, 13 organisations now have until June to respond to a coroner's report.

Long-term implications may be underestimated, and new data show relatively low medication use.

A new study finds that prior authorization requirements vary widely across major insurers and suggests large language models could help streamline how authorization rules are interpreted and processed.

News All Time

How Lifeline Brought the AMR Crisis to the London Stage

Real doctors joined the London cast of Lifeline the Musical to bring the growing threat of antimicrobial resistance to wider audiences.

Cardiorenal Benefits of GLP-1s Found in Type 1 Diabetes

A large database study shows lower risk for major adverse cardiovascular events and end-stage kidney disease, with no increase in adverse events.

Germany Flags Safety Risks in ‘Vitamin Drip’ Trend

BfArM warns ‘vitamin drips’ can cause hypervitaminosis, electrolyte imbalance, allergic reactions up to anaphylaxis, fluid overload, and IV complications such as air embolism.

Arterial Widening, Not Blockage, Tied to Common Stroke

Arterial widening, not vessel blockage, is strongly associated with lacunar stroke, a finding that could explain why conventional antiplatelet therapies offer limited benefit.

Single-Pill Hypertension Therapy Remains Underutilized

Single-pill combination therapy remains underused as the initial treatment for adults newly diagnosed with hypertension, despite repeated guideline recommendations.

Maternal Diabetes in Pregnancy Tied to CVD Risk in Children

Maternal diabetes during pregnancy is associated with an increased risk for cardiovascular disease in offspring, and part of this association is explained by birth complications.

Polycystic Ovary Syndrome Demands Multidisciplinary Approach

Along with endocrinologists, ob/gyns, mental health professionals, and nutritionists, dermatologists play a key role in addressing polycystic ovary syndrome, experts say.

Time in Target Range Metric May Aid in CKD Management

The urine albumin/creatinine ratio time in target range predicts cardiovascular outcomes in people with and without chronic kidney disease.

SSRI vs NDRI: Which Is Better for Post-Stroke Depression?

Bupropion is linked to lower suicidal ideation risk but higher odds of demoralization and apathy vs fluoxetine in post-stroke depression, new research shows.

TADV Saves Limbs in No-Option CLTI Patients

More than 80% of no-option chronic limb-threatening ischemia patients avoided amputation for 6 months after the procedure while enjoying improved wound healing and reduced pain.

Underground Hospitals: Is Combat Medicine Entering a New Era?

Ukrainian clinicians increasingly rely on protected underground facilities as drone threats complicate evacuation and strain traditional battlefield treatment models.

France Focuses on Drugs That Raise Fall Risk in Older Adults

Long-term benzodiazepines and anticholinergics drive falls in seniors; prioritize nonpharmacologic care and deprescribing to cut injuries and hospitalizations.

Uraemic Marker Predicts Mortality After Kidney Transplant

Plasma levels of symmetric dimethylarginine are independently associated with an increased risk for mortality in adult kidney transplant recipients, a prospective study finds.

GLP-1 Drugs Tied to Cardiovascular Benefits in T1D

Adults with T1D who receive GLP-1-based therapy may have a lower risk for adverse cardiovascular outcomes and no significant increase in diabetic ketoacidosis compared with those who do not.

Transient Neurologic Symptoms: What Clinicians Miss

Speakers warn that transient neurologic events may conceal high-risk vascular disease, seizures, or amnestic syndromes requiring rapid evaluation.

SGLT2 Inhibitors Show Similar Cardiorenal Benefits

Empagliflozin and dapagliflozin show similar effectiveness in preventing cardiorenal outcomes among patients with type 2 diabetes without prior cardiovascular or renal disease.

Recommended News For You

Should the UK introduce targeted prostate cancer screening? The case for and against

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

Fear of hair loss might cause some to reject cancer treatment

Telemedicine services linked to reducing excess mortality

How the skin cancer virus outperforms the replication of host cells.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

Recommended Articles For You

Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts 

Inside Oncology Trials: From Protocol to Progress in Cancer Research and Care 

Radiation in Oncology: Advances, Applications, and Accessibility 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.

1.

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training

2.

Hemoglobin C: Understanding its Role in Sickle Cell Disease

3.

Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging

4.

Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer 

5.

The Growing Challenge of Haematological Malignancies in Older Adults

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot